Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer

(MedPage Today) -- SAN ANTONIO -- Adding tucatinib (Tukysa) to trastuzumab emtansine (T-DM1; Kadcyla) reduced the risk of disease progression or death by 24% in previously treated HER2-positive breast cancer patients with locally advanced unresectable...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news